Related Experiment Video
Updated: Sep 21, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Late-stage Diversification of HIV-1 Protease Inhibitor via SuFEx Click Chemistry
Bipin Khanal1, Pavel Yamanushkin1, Brian Gold1
1Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, New Mexico, 88003, USA.
Abstract:
The global HIV/AIDS epidemic continues to demand durable antiretroviral therapies. HIV-1 protease (HIV-PR) remains a central target, and although darunavir (DRV) exhibits exceptional resilience, resistance evolution necessitates continued innovation. Building on DRV's success, structural modifications at key positions have yielded promising derivatives. In this work, we report the design and synthesis of over 20 DRV derivatives incorporating pyrazole and amino acid motifs at the P2' position. These substituents were introduced to strengthen interactions within the protease active site and expand opportunities for resistance coverage. Sulfur(VI) fluoride exchange (SuFEx) chemistry was employed as a robust late-stage diversification strategy, enabling efficient coupling and rapid library generation. This approach highlights the potential to access structurally diverse HIV-1 protease inhibitors, laying the groundwork for the development of next-generation therapeutics.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Retrovirus Life Cycles
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
Viral Mutations

